CDER “De-Layering” In Second Half 2003, Following Incorporation Of CBER
Executive Summary
FDA's Center for Drug Evaluation & Research will undergo a "de-layering" in mid- to late 2003 as part of FDA's overall review of management functions
You may also be interested in...
McClellan’s Policy Clout Creates Big Shoes To Fill At FDA
The planned reorganization of FDA following Commissioner Mark McClellan's departure reflects an emphasis on interactions with Capitol Hill and the Administration
McClellan’s Policy Clout Creates Big Shoes To Fill At FDA
The planned reorganization of FDA following Commissioner Mark McClellan's departure reflects an emphasis on interactions with Capitol Hill and the Administration
FDA Commissioner’s Office To Be Re-aligned Further Under Booz Allen Plan
FDA's Office of the Commissioner will be re-aligned further by the end of fiscal year 2003 with the assistance of Booz Allen Hamilton consultants